Invicro announced the acquisition of UK-based Imanova. Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.
“Joining forces with the phenomenal research team at Imanova expands our translational, analytic and geographic offering. Our groups share a common mission of improving research trials through the development and application of quantitative imaging biomarkers,” said Dr. Jack Hoppin, Invicro’s Co-Founder and CEO. “Our combined research teams hold a collective pride in the development of novel offerings in discovery as well as the engineering of scalable, reproducible solutions for deployment in late-phase development.”
Imanova is a leader in the application of PET and MR imaging, with a focus on translational research to support the transition from pre-clinical studies to Phase I/II studies in humans. The services of the combined business covers the entire translational spectrum, ranging from novel biomarker evaluation and development in early discovery to late-phase clinical trials support.
“Invicro develops innovative analytical approaches for clinical trials, which are highly complementary with our own. Combining Invicro’s and Imanova’s analytics platforms means we have a best-in-class imaging informatics team to help reduce risk in drug development,” said Dr. Kevin Cox, Imanova’s CEO. “As a combined enterprise we will be a truly translational quantitative biomarker company, with an expanding late-phase clinical trial offering, able to meet the needs of a growing global market.”